灯盏花素注射液治疗急性脑梗死的临床证据与GRADE评价
结果显示联合DZHS可提高NIHSS总有效率、改善临床症状与神经功能缺损、降低不良反应发生率,GRADE证据质量总体为低,需进一步高质量RCT验证。
要点
- 灯盏花素注射液联合常规治疗可提高急性脑梗死患者NIHSS总有效率。
- 联合治疗可改善临床症状体征并降低NIHSS评分,减少神经功能缺损。
- 联合治疗不良反应发生率降低,但GRADE证据质量总体为低。
核心结论
- 灯盏花素注射液联合常规治疗有条件推荐用于提高急性脑梗死NIHSS总有效率、改善临床症状和神经功能缺损并降低不良反应发生率,未发现严重不良反应。
- GRADE评价提示总体证据质量较低,仍需大规模、设计良好的高质量RCT证实。
研究设计与样本
- 研究为Meta分析,检索Cochrane Library、PubMed、Embase、Web of Science及四个中文数据库筛选灯盏花素注射液治疗急性脑梗死的RCT。
主要发现
- 与对照组相比,DZHS组NIHSS总有效率更高(RR=1.23,95%CI=1.19–1.28,P<0.001;RR=1.29,95%CI=1.21–1.38,P<0.001)。
- DZHS组临床症状体征改善(RR=1.17,95%CI=1.10–1.24,P<0.001;RR=1.25,95%CI=1.11–1.42,P<0.001)。
- DZHS组不良反应发生率降低(RR=0.50,95%CI=0.26–0.98,P=0.044)。
- DZHS组NIHSS评分下降(WMD=-3.30,95%CI=-3.86至-2.73,P<0.001)。
关键数值与推荐
- GRADE评估显示总体证据质量低。
- PROSPERO注册号CRD42019128856。
临床怎么用
- 在急性脑梗死常规治疗基础上,可考虑联合灯盏花素注射液以改善神经功能缺损和临床症状。
- 临床决策时应结合GRADE低证据质量的提示,个体化评估获益与风险。
局限性
- GRADE评价提示总体证据质量较低。
- 需进一步大规模、设计良好的高质量RCT确认阳性结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Breviscapine injections (DengZhanHuaSu, DZHS) is a famous Chinese patent medicine authorized by China Food and Drug Administration, which is widely used to treat acute cerebral infarction (ACI) in China. AIM OF THE STUDY: In the present study, meta-analysis has been performed in determining the efficacy and safety of DZHS combined with conventional treatment (CT) for ACI and GRADE assessment. MATERIALS AND METHODS: Randomized controlled trials (RCTs) testing the use of DZHS for treating ACI were screened by searching the databases of the Cochrane Library, PubMed, Embase, and Web of Science as well as four Chinese databases. Meta-analysis was carried out with RevMan 5.3 and Stata 16.0 software. The quality of research evidence was assessed by the GRADEprofiler (GRADEpro version: 3.6). RESULTS: Forty-three studies (n = 4618) were included. When compared to the control groups, the total effective rate of the national institutes of health stroke scale (NIHSS) was higher in the experimental group with DZHS (RR = 1.23, 95% CI = 1.19 to 1.28, P < 0.001; RR = 1.29, 95% CI = 1.21 to 1.38, P < 0.001); clinical symptoms and signs were improved in the experimental group with DZHS (RR = 1.17, 95% CI = 1.10 to 1.24, P < 0.001; RR = 1.25, 95% CI = 1.11 to 1.42, P < 0.001); the incidence of adverse reactions was reduced in the experimental group with DZHS (RR = 0.50, 95% CI = 0.26 to 0.98, P = 0.044); and the NIHSS score was decreased in the experimental group with DZHS (WMD = -3.30, 95% CI = -3.86 to -2.73, P < 0.001). CONCLUSIONS: DZHS combined with CT is conditionally recommended to improve the total effective rate of the NIHSS, clinical symptoms, and neurological deficits and reduce the incidence of adverse reactions, and no serious adverse reactions were noted. The GRADE assessment indicates that the overall certainty quality of evidence is low. Further large-scale, well-designed and high-quality RCTs are needed to confirm the positive results. PROSPERO registration No. CRD42019128856.
引用
- Lyu J, Xie Y, Sun M, et al. Clinical evidence and GRADE assessment for breviscapine injection (DengZhanHuaSu) in patients with acute cerebral infarction. J Ethnopharmacol. 2020. PMID: 32726677. doi:10.1016/j.jep.2020.113137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。